- Home
- TARS vs GOF Comparison
TARS vs GOF Comparison
Compare TARS & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARS | GOF |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | TARS | GOF |
|---|---|---|
| Price | $59.11 | $10.68 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $89.00 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $56.43 | N/A |
| Revenue Next Year | $30.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $10.50 |
| 52 Week High | $85.25 | $15.20 |
Technical Indicators
Market Signals| Indicator | TARS | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 37.03 |
| Support Level | $59.16 | $10.54 |
| Resistance Level | $67.14 | $11.02 |
| Average True Range (ATR) | 4.27 | 0.09 |
| MACD | -0.78 | -0.00 |
| Stochastic Oscillator | 31.00 | 9.49 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.